Biomarker Profiling Based on Previous FoundationOne CDx Results: An FAQ

Earlier this year, LUNGMAP eligibility was expanded to allow reanalysis of results from a previous commercial FoundationOne CDx solid tumor test (reported September 1, 2019 or later) to be used for biomarker profiling instead of a tissue submission. This option can be easier for site coordinators and has the added benefit of not using tissue resources that are sometimes very limited. It can also open up the trial to patients who don’t have archival tissue available and cannot undergo a biopsy.

The Lung-MAP FAQ document has been updated to include FAQs regarding the reanalysis of commercial FoundationOne CDx reports; please review it on the Required Lung-MAP Training page on the SWOG website.

Some additional Q&As compiled by the Lung-MAP data coordinators include:

Q: Can results from a commercial FoundationOne CDx test done on a bone specimen be used for reanalysis on LUNGMAP?

A: Yes, successful results from FoundationOne CDx can be used for reanalysis as long as the solid tissue test was done on a cell block created from pleural fluid or another cytology specimen.

Q: Can results from a commercial FoundationOne Heme report be used if done on a solid tissue specimen?

A: No, FoundationOne Heme results cannot be used for reanalysis and do not meet the LUNGMAP eligibility criterion.

Q: If the FoundationOne CDx report lists the diagnosis as something other than NSCLC (for example, carcinoma of an unknown primary), will this be allowed?

A: Potentially; please provide documentation for the change in diagnosis to Foundation Medicine at lung.map@foundationmedicine.com after the reanalysis request is submitted.

S1800D Approaches the Launch Pad; S1900F Coming Soon

Lung-MAP sub-study S1800D is in its final review stages and is expected to activate in the first quarter of 2022. It will test N-803 (ALT-803) plus pembrolizumab versus standard of care in patients with stage IV or recurrent NSCLC previously treated with anti-PD-1 or anti-PD-L1 therapy. Register now to attend an S1800D training webinar Thursday, January 13, 12-1 pm CST. And download the S1800D training slides from the Required Lung-MAP Training page.

S1900F is a study of carboplatin and pemetrexed with or without selpercatinib in patients with RET fusion-positive disease who have progressed on previous RET-directed therapy. It is expected to open by spring. Stay tuned!
Lung-MAP by the Numbers: New Infographic Available!

The Lung-MAP team has assembled a full-page infographic that provides a numerical overview of study progress. You can download a full-size PDF you can print out for your team!

The new Lung-MAP protocol has logged:
- 2,267 screening registrations
- 1,033 sub-study assignments
- 319 sub-study registrations

**TOP-ACCRUING SITES***

1. UPMC Hillman Cancer Center Pittsburgh, PA 138
2. UNM Comprehensive Cancer Center Albuquerque, NM 44
3. Wilmot Cancer Institute Rochester, NY 43
4. Mercy Medical Center Canton, OH 38
5. Missouri Baptist Medical Center St. Louis, MO 33
6. Roswell Park Comprehensive Cancer Center Buffalo, NY 27
7. Markey Cancer Center Lexington, KY 25
8. Edwards Comprehensive Cancer Center Huntington, WV 25
7. Baystate Medical Center Springfield, MA 25
8. Stephenson Cancer Center Oklahoma City, OK 24
9. Good Samaritan Hospital Cincinnati, OH 24
9. Virginia Cancer Institute Richmond, VA 23
9. Eastern Maine Medical Center Cancer Care Brewer, ME 23
9. VA Connecticut Healthcare System — West Haven West Haven, CT 23
9. Essentia Health Duluth, MN 23
10. Northside Hospital Cancer Institute Atlanta, GA 22

*As of December 12, 2021

**Highly Motivated Expert Partners for Trial Conduct**

- 13 PARTNERING PRECISION MEDICINE DIAGNOSTIC COMPANIES AND LEADING PHARMACEUTICAL COMPANIES
- 13 INVESTIGATIONAL DRUGS OR DRUG COMBINATIONS TESTED
- 16 INITIATED 14 COMPLETED SUB-STUDIES CONDUCTED
- 10 AGENTS AGAINST SPECIFIC TUMOR MUTATIONS/GENETIC SIGNATURES TESTED IN NSCLC
- 12 MONTH AVERAGE SUB-STUDY STAND UP TIME FROM APPROVAL BY THE LUNG-MAP DRUG SELECTION COMMITTEE TO ACTIVATION
- 22 MONTH AVERAGE TIME TO TARGET ACCRUAL COMPLETION FOR ~80 PERSON STUDY, DRIVEN BY BIOMARKER PREVALENCE
- 13 INVESTIGATIONAL DRUGS OR DRUG COMBINATIONS TESTED
- 10,000+ ANNOTATED SPECIMENS IN A TISSUE BANK TO ALLOW DEEPER SCIENTIFIC STUDIES TO INFLUENCE FUTURE TRIALS
- 13 PARTNERING PRECISION MEDICINE DIAGNOSTIC COMPANIES AND LEADING PHARMACEUTICAL COMPANIES
- 8 ORGANIZATIONS, INCLUDING NCI AND PHR, WORKING TOGETHER TO CONDUCT AND OVERSEE THE STUDY
- 10,000+ ANNOTATED SPECIMENS IN A TISSUE BANK TO ALLOW DEEPER SCIENTIFIC STUDIES TO INFLUENCE FUTURE TRIALS
- 30+ PUBLICATIONS AND ABSTRACTS

**Additional Benefits of Lung-MAP**

- SHARED COSTS AND RISKS OF TESTING THERAPEUTICS FOR COMPANIES
- FOSTERING DRUG COMBINATION COLLABORATIONS BETWEEN COMPANIES
- ACCELERATED TIMEFRAMES FOR EVALUATION OF TREATMENT EFFICACY DUE TO THE LARGE NETWORK
- STRONG SUPPORT FROM THE FDA WITH ABILITY FOR STUDIES TO HAVE REGULATORY INTENT

**Nearly 30 Public and Private Collaborators and Supporters in Partnership since 2014**

- 13 PARTNERING PRECISION MEDICINE DIAGNOSTIC COMPANIES AND LEADING PHARMACEUTICAL COMPANIES
- 13 INVESTIGATIONAL DRUGS OR DRUG COMBINATIONS TESTED
- 16 INITIATED 14 COMPLETED SUB-STUDIES CONDUCTED
- 10 AGENTS AGAINST SPECIFIC TUMOR MUTATIONS/GENETIC SIGNATURES TESTED IN NSCLC
- 12 MONTH AVERAGE SUB-STUDY STAND UP TIME FROM APPROVAL BY THE LUNG-MAP DRUG SELECTION COMMITTEE TO ACTIVATION
- 22 MONTH AVERAGE TIME TO TARGET ACCRUAL COMPLETION FOR ~80 PERSON STUDY, DRIVEN BY BIOMARKER PREVALENCE

**Highly Motivated Expert Partners for Trial Conduct**

**CONTACT US**

**General Medical Questions** [LUNGMAP@swog.org](mailto:LUNGMAP@swog.org)

**Protocol & Regulatory Questions**
lgildner@swog.org or jbeeler@swog.org

**Eligibility & Data Submission Questions**
LUNGMAPQuestion@crab.org

**Central Monitoring Questions**
centralmonitorquestion@crab.org

**Quality Assurance Auditing Questions**
gamail@swog.org

**Funding Questions**
funding@swog.org

**S1900E Study Chairs**
S1900EMedicalQuery@swog.org